ALLR Allarity Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1860657 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,938.3%
Net margin-4,493.7%
FCF margin-3,785.4%
EBITDA margin—
Returns
ROE-322.7%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets108.3%
Debt / equity—
Current ratio0.91x
Interest coverage-6.83x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue20.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $320,000 | $0 | — | — | — |
| Gross profit | — | — | — | -$2.27M | — |
| R&D expense | $6.60M | $6.10M | $7.10M | $6.93M | $14.20M |
| SG&A expense | $6.32M | $11.44M | $10.03M | $9.96M | $12.36M |
| Operating income | -$12.61M | -$27.24M | -$17.13M | -$34.46M | -$26.56M |
| Interest expense | $185,000 | $653,000 | $498,000 | $223,000 | $99,000 |
| Pretax income | -$11.23M | -$24.90M | -$11.82M | -$17.58M | — |
| Income tax | $0 | -$381,000 | $83,000 | -$1.52M | $133,000 |
| Net income | -$11.23M | -$24.52M | -$11.90M | -$16.06M | -$26.65M |
| EBITDA | — | -$27.23M | -$17.09M | -$34.40M | -$26.45M |
| EPS (basic) | -0.78 | -15.65 | -6,031.31 | -3,093.42 | -4.19 |
| EPS (diluted) | — | — | -10.26 | -3,093.42 | -4.19 |
| Weighted avg. shares (diluted) | — | — | 1.99M | 6,805 | 6.36M |
| Banking | |||||
| Net interest income | — | — | — | — | -$1.35M |
| Balance sheet | |||||
| Cash & equivalents | $14.69M | $19.53M | $166,000 | $2.03M | $19.55M |
| Current assets | $17.93M | $22.34M | $1.97M | $4.97M | $21.40M |
| PP&E, net | $330,000 | $309,000 | $20,000 | $21,000 | $8,000 |
| Intangibles | — | $0 | $9.87M | $9.55M | $28.14M |
| Total assets | $18.26M | $22.65M | $11.86M | $14.54M | $49.63M |
| Current liabilities | $8.43M | $10.84M | $14.17M | $11.22M | $20.72M |
| Short-term debt | $0 | — | $250,000 | — | — |
| Long-term debt | — | — | $2.69M | $2.64M | — |
| Total debt | — | — | $2.94M | $2.64M | — |
| Total liabilities | $8.43M | $10.84M | $14.61M | $12.65M | $30.85M |
| Shareholders' equity | $9.83M | $11.81M | -$2.75M | -$113,000 | $18.15M |
| Net debt | — | — | $2.77M | $615,000 | — |
| Shares outstanding | 16.08M | 7.30M | 9,812 | 11,356 | 8.10M |
| Cash flow statement | |||||
| Operating cash flow | -$14.82M | -$17.35M | -$12.74M | -$16.82M | -$14.89M |
| Capital expenditure | $8,000 | $298,000 | $0 | $18,000 | — |
| Free cash flow | -$14.83M | -$17.65M | -$12.74M | -$16.84M | — |
| Investing cash flow | -$8,000 | -$298,000 | $0 | $791,000 | $1.00M |
| Financing cash flow | $10.65M | $36.79M | $10.99M | -$1.31M | $33.82M |
| Depreciation & amortization | — | $9,000 | $37,000 | $60,000 | $106,000 |
| Stock-based compensation | $482,000 | $71,000 | -$71,000 | $1.75M | $6.37M |
| Share buybacks | $3.19M | $0 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.